BioAlliance Pharma Announces Two New Key Steps in the Development of Its AMEP® Biotherapy

PARIS--(BUSINESS WIRE)-- Regulatory News:

BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to orphan oncology products and specialty products, today announces the validation by the French drug agency (Afssaps) of its application for a phase I/II clinical trial with Amep® in the metastatic melanoma, and the signature of a partnership agreement for the development of its biotherapy with the Department of Oncology of the Herlev Hospital of Copenhagen.

Submitted end of January 2012, the phase I/II clinical trial application follows the positive preliminary results of a first phase I trial via local administration (intratumoral) in patients with metastatic melanoma. This phase I/II trial, to be conducted on a European level, aims at evaluating the safety and efficacy profile of the Amep® biotherapy via systemic route (intramuscular) in the same indication. The growing incidence of metastatic melanoma and the short survival duration of patients make this cancer a disease with a very strong therapeutic need.

Moreover, BioAlliance Pharma and the Herlev Hospital of Copenhagen have recently signed a partnership agreement to conduct a complementary phase I clinical trial with Amep® in Denmark. This trial, currently under evaluation by the Danish Medicines Agency, aims at evaluating the safety and the efficacy of the Amep® biotherapy in patients with different types of metastatic solid tumors. It will be conducted by Dr Julie Gehl, Oncologist, Clinical Associate Research Professor at University of Copenhagen, who was already actively involved in the first phase I trial via local route, and thus reinforces the development plan of this asset.

“As planned, we are pursuing the European development of a particularly innovative therapy, developed and valued in a consortium associating academic research, industrials and melanoma clinicians, and co-financed by OSEO's Strategic Industrial Innovation Program”, declares Judith Greciet, CEO of BioAlliance Pharma. “The collaboration with a great European oncology centre, in partnership with Dr Julie Gehl, to evaluate the interest of Amep® in other types of cancers is an interesting opportunity that reinforces the value of this key asset. The receivability of the phase I/II trial via intramuscular route, together with this partnership agreement, represent two key achievements in the clinical development of Amep®, an original biotherapy of our strategic portfolio”.

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)
Sitavir® (Acyclovir LauriadTM) (labialis herpes): Positive phase III final results; registration status
Fentanyl LauriadTM (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products
Livatag® (Doxorubicin Transdrug™) in primary liver cancer: Authorization for Phase III clinical trial
Clonidine LauriadTM (mucositis): Phase II on going
AMEP™ (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2011 Reference Document filed with the AMF on April 24, 2012, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).



CONTACT:

BioAlliance Pharma SA
Judith Greciet, CEO
Tel +33 1 45 58 76 00
[email protected]
or
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
[email protected]
or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
[email protected]

KEYWORDS:   Europe  France

INDUSTRY KEYWORDS:   Health  Clinical Trials  Hospitals  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.